An interventional study of Ginseng-notoginseng Containing Supplement in Chronic Fatigue, sponsored by Tung Leong FONG. Not yet recruiting at 1 site in Nigeria. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Tung Leong FONG · Not applicable, Interventional, and Supportive care
This study aims to find out whether a dietary supplement containing ginseng and notoginseng (GIN-201) can safely reduce persistent fatigue in adults. Chronic fatigue is a lasting feeling of tiredness that rest does not relieve which affects about 10% of adults in Hong Kong and can harm sleep, thinking, and quality of life. Ginseng and notoginseng are traditional Chinese medicine herbs thought to boost energy, and early research suggests they may help with fatigue, but their combined effect has not been tested in people.
The study will recruit 130 adults aged 30 to 75 who report fatigue and poor sleep. Participants will be randomly assigned to one of two groups: one group takes GIN-201 capsules (4 per day) for 6 weeks, while the other group waits 6 weeks before starting the same supplement. Both groups will then be followed for another 6 weeks. Fatigue, sleep, mood, quality of life, and sexual/menopausal symptoms will be measured with standard questionnaires, and blood tests will check for markers of inflammation, stress, aging, and mitochondrial health, as well as for safety.
The main question the study is trying to answer is: Does taking GIN-201 for 6 weeks reduce fatigue more than no treatment, and is it safe? The researchers hypothesize that GIN-201 will reduce fatigue in adults with persistent fatigue. The study will also explore whether changes in blood biomarkers are linked to any benefits, which may help identify who is most likely to respond to the supplement.
2,232 studies on the registry are indexed under Fatigue; 428 are open to participants now.
This study's planned enrollment of 130 is above the median of 54 across 1,760 interventional studies indexed under Fatigue.
Browse Fatigue studies →Tung Leong FONG is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Ginseng-notoginseng Containing Supplement (GIN-201) in 4 capsules, once per day, for 6 weeks, according to the manufacturer's guidelines, followed by a 6-week follow-up.
Dietary Supplement: Ginseng-notoginseng Containing Supplement
The waiting list control group will wait for 6 weeks after the randomization, and then start to receive GIN-201 in 4 capsules, once per day, for 6 weeks, followed by a 6week follow-up.
GIN-201 is a capsule supplement produced via microbial fermentation technology in a GMP-certified Hong Kong facility, converting ginseng and notoginseng into a highly bioavailable extract; It is reported to support mitochondrial function, DNA repair, NAD+ elevation, and antioxidant defense. Participants take 4 capsules orally once daily for 6 weeks, followed by a 6-week follow-up.
Chalder Fatigue Score (CFS)
Bimodally scored 0-4 on an 11-item scale; higher scores indicate greater fatigue.
Time frame: From enrollment to 6 weeks
Chalder Fatigue Score (CFS)
Bimodally scored 0-4 on an 11-item scale; higher scores indicate greater fatigue.
Time frame: From enrollment to 6 weeks and 12 weeks
Fatigue Severity Score (FSS)
Likert score 1-7 on a 9-item scale; higher scores indicate more severe fatigue.
Time frame: From enrollment to 6 weeks and 12 weeks
PROMIS Short Form Fatigue 7A
5-point Likert scale across 7 items; higher scores indicate greater fatigue.
Time frame: From enrollment to 6 weeks and 12 weeks
36-Item Short-Form Health Survey (SF-36)
Range 0-100; higher scores indicate better health status.
Time frame: From enrollment to 6 weeks and 12 weeks
Hospital Anxiety and Depression Scale (HADS)
Range 0-21; higher scores indicate more severe symptoms.
Time frame: From enrollment to 6 weeks and 12 weeks
Pittsburgh Sleep Quality Index (PSQI)
Range 0-21; higher scores indicate worse sleep quality.
Time frame: From enrollment to 6 weeks and 12 weeks
Brief Male Sexual Function Inventory (BMSFI) / Menopause Rating Scale (MRS)
BMSFI: 11-item in 5 divisions; higher score indicates more satisfied sexual function (men). MRS: Likert score 0-4 for 11 items; higher indicates severer menopause symptoms (women).
Time frame: From enrollment to 6 weeks and 12 weeks
Plan to share: Yes — De-identified individual participant data underlying the results reported in the primary study publication will be shared, together with a data dictionary. Shared data will include participant characteristics, treatment allocation, Chalder Fatigue Score and other fatigue questionnaire scores, quality-of-life (SF-36), psychological (HADS), sleep (PSQI), and sexual/menopausal symptom (BMSFI/MRS) scores, biomarker results (inflammation, stress, neurotrophic, aging, and mitochondrial health), adherence data, and adverse event data used in the published analyses. Direct identifiers and the participant identification linkage file will not be shared. Access will be provided to qualified researchers following approval of a research proposal and execution of a data use agreement. Sharing will be subject to any required Institutional Review Board (IRB) and institutional approvals and must be consistent with participant consent.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: De-identified individual participant data and the selected supporting documents will be available from publication of the primary study results until five years after study completion.
Access criteria: De-identified individual participant data underlying the published results, the data dictionary, and the selected supporting documents will be available to qualified researchers upon reasonable request. Requests should be submitted by email to the principal investigator and include a methodologically sound research proposal and statistical analysis plan. The principal investigator will review requests for scientific merit, feasibility, and consistency with participant consent and institutional requirements. Approved researchers may use the data only for analyses specified in the approved proposal. Access will require a signed data use agreement and any necessary IRB and institutional approvals. Data will be provided through secure transfer.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
Of 936 non-industry interventional studies with no phase under Fatigue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 24 months is above that.
Counting every sponsor, half of 989 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tung Leong FONG